Trump’s drugmaker deals may save economy $529B over 10 years, White House says
The White House estimates that President Donald Trump's deals with pharmaceutical companies to lower US prescription drug prices could save $529 billion over 10 years. The analysis, done by the White House Council of Economic Advisers, also estimated that federal and state governments could save $64.3 billion on Medicaid during the next decade.
The White House estimates that President Donald Trump's deals with pharmaceutical companies could save $529 billion over 10 years. The analysis was done by the White House Council of Economic Advisers. Trump's 'most favored nation' policy aims to lower US prescription drug prices to match those in other countries. The administration estimates that federal and state governments could save $64.3 billion on Medicaid during the next decade. Few details of the deals with 17 leading pharmaceutical companies have been made public, making it hard to verify the projected savings. Democratic lawmakers have challenged the administration's claims, questioning the data and calling for disclosure of the agreements' terms.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.